BioCentury
ARTICLE | Clinical News

SDP051: Phase I data

February 10, 2014 8:00 AM UTC

A placebo-controlled Phase I trial in healthy volunteers showed that single ascending-doses of SDP051 were well tolerated up to 10 mg/kg with no evidence of significant adverse events. Next year, Adhe...